In the NRG LU005 trial, patients receiving BID radiation or PCI appeared to have better outcomes. The speaker warns this is likely because they were younger and healthier—a result of selection bias, not superior treatment. This serves as a critical caution against using non-randomized subgroup data for clinical decisions.

The CREST trial showed benefit driven by patients with carcinoma in situ (CIS), while the Potomac trial showed a lack of benefit in the same subgroup. This stark inconsistency demonstrates that subgroup analyses, even for stratified factors, can be unreliable and are a weak basis for regulatory decisions or label restrictions.

While smaller trials like KEYNOTE-905 can show dramatic results, they are subject to more statistical noise. Larger, thousand-patient studies like B15 and Niagara, with narrower confidence intervals, are considered closer to the true effect size and provide a more stable foundation for establishing the standard of care.

The FDA's critique of both CREST and Potomac trials highlights that while event-free survival (EFS) endpoints were met, the lack of improvement in overall survival or prevention of muscle-invasive disease makes the risk/benefit profile questionable for an early-stage cancer, where treatment-related harm is a primary concern.

In the SUNRISE 2 trial, 44% of patients had no detectable tumor after pre-treatment resection. This high baseline inflates the final clinical complete response (CR) rates (e.g., 59% in the control arm), making CR a misleading indicator of the actual therapeutic benefit, which was a much smaller improvement over baseline.

Current bladder cancer trials often fail to differentiate between patients with primary resistance (never responded) versus acquired resistance (responded, then progressed). Adopting this distinction, common in lung cancer research, could help identify patient subgroups more likely to benefit from immunotherapy re-challenge and refine trial eligibility criteria.

An expert argues forcefully that the PD-L1 biomarker should be "ditched" in bladder cancer. Citing its repeated failure to predict overall survival benefit across multiple major trials, it is deemed an oversimplified and unreliable tool that leads to both over- and under-treatment of patients.

The LEAP-010 trial showed a combination therapy improved tumor response and progression-free survival but failed to improve overall survival, the ultimate measure of benefit. This highlights the risk of relying on surrogate endpoints, which can be misleading, especially when a treatment adds significant toxicity.

Despite data from kidney cancer showing immunotherapy re-challenge is often ineffective, oncologists admit to using it in urothelial cancer. This highlights a clinical conflict where the desire to use a powerful drug class outweighs the lack of supporting evidence, especially in specific, confusing patient scenarios.